Iovance Biotherapeutics (IOVA) Cash from Operations Growth (1y) (2011 - 2026)
Iovance Biotherapeutics (IOVA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.58% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -119.28% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 100.14% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 151.70% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 56.79% |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 9.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.83% |
| Mar 31, 2026 | 30.47% |
| Dec 31, 2025 | 28.29% |
| Sep 30, 2025 | -33.52% |
| Jun 30, 2025 | 31.52% |
| Mar 31, 2025 | 15.20% |
| Dec 31, 2024 | 12.71% |
| Sep 30, 2024 | 29.86% |
| Jun 30, 2024 | -4.77% |
| Mar 31, 2024 | -22.51% |
| Dec 31, 2023 | -8.11% |
| Sep 30, 2023 | -32.10% |
| Jun 30, 2023 | -21.02% |
| Mar 31, 2023 | -35.25% |
| Dec 31, 2022 | -44.24% |
| Sep 30, 2022 | -10.32% |
| Jun 30, 2022 | -43.75% |
| Mar 31, 2022 | -18.29% |
| Dec 31, 2021 | 14.11% |
| Sep 30, 2021 | -42.40% |